MRC1 and neoplasm: Indeed, it is reported that tumors with MMR deficiency have 10 to 100 times more somatic mutations than MMR-proficient tumors and this hypermutation state could lead to a high neoantigen load and consequent activation of the immune system and tumor destruction [38].